Form: 8-K

Current report

March 9, 2026

Documents

Exhibit 99.1

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

•
Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancer
•
CRB-701 data for both indications is expected in mid-2026 with focus on durability and patient stratification
•
Reported 14-day CRB-913 SAD/MAD data demonstrating potent and rapid weight loss of 2.9% with favorable GI safety
•
On schedule to complete 12-week CRB-913 obesity study (n=240) in summer 2026
•
Completed $75 million public offering in Q4 2025 extending cash runway into 2028

 

Norwood, MA, March 9, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage company focused on promising new therapies in oncology and obesity, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2025.

"Our encouraging data readouts for CRB-701 and CRB-913 in the fourth quarter of 2025 set the stage for a potentially transformative 2026. This summer we anticipate key data readouts for both programs that we expect will elucidate their differentiated efficacy and safety profiles, as well as potential clinical utility and commercial opportunities,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “The clinical responses we are generating in HNSCC and cervical cancer patients with CRB-701, a highly stable Nectin-4 ADC, highlight its potential in treating these challenging tumor types. In parallel, the rapid weight loss and favorable GI tolerability we’ve seen with CRB-913 suggest it could provide a novel long-term weight management solution for people struggling with chronic obesity.”

Key Corporate and Program Updates

 

CRB-701 is a next-generation, highly stable Nectin-4 targeting ADC being developed to treat HNSCC and cervical cancer. The U.S. Food and Drug Administration (FDA) has granted Fast Track designations to CRB-701 for the treatment of both cancer types. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China.

 

•
Encouraging CRB-701 Phase 1/2 data in Q4 2025. Corbus presented dose optimization data at the 2025 European Society for Medical Oncology Congress (ESMO 2025). Highlights included:
o
Unconfirmed Objective Response Rate with CRB-701 at the 3.6 mg/kg dose: HNSCC - 47.6%, Cervical cancer - 37.5%, and Bladder - 55.6%.
o
Favorable safety and tolerability with no grade 4 or 5 treatment-related adverse events.
o
Markedly low levels of peripheral neuropathy and skin toxicity.
o
Link here (link: https://ir.corbuspharma.com/news-events/press-releases/detail/452/corbus-pharmaceuticals-presents-crb-701-robust-clinical-responses-in-hnscc-and-cervical-cancers-at-esmo25) for CRB-701 ESMO data press release and here (link: https://lifescievents.com/event/vak208zhgo/) for archived KOL event discussing the findings.

 

•
Anticipated catalysts for CRB-701 in 2026:
o
Provide update in Q1 2026 from discussions with FDA regarding registrational study protocols for HNSCC and cervical cancer.
o
Report monotherapy data in mid-2026 with a key focus being durability data and patient stratification.
o
Generate CRB-701 + Keytruda combination data in first line (“1L”) HNSCC patients in Q4 2026.

 

CRB-913 is a highly peripherally restricted oral CB1 inverse agonist for the treatment of obesity.

 

•
Encouraging CRB-913 data in Q4 2025. Corbus completed a single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study in December 2025. SAD portion: n=64 across 8 cohorts; MAD portion: n=48 across 4 cohorts. Highest SAD dose tested was 600 mg/day and highest MAD dose tested was 150 mg/day. Highlights include:
o
Weight loss of 2.9% (placebo adjusted) at 14-days in dedicated 150 mg/day obesity cohort (n=12). Weight loss started early and deepened with time. Safe and well-tolerated across all cohorts and all doses studied.
o
Very favorable GI profile with no reports of vomiting, constipation or nausea.
o
Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative.
o
Link here (link: https://ir.corbuspharma.com/news-events/press-releases/detail/458/corbus-pharmaceuticals-reports-results-from-phase-1a-study-of-oral-cb1-inverse-agonist-crb-913-for-the-treatment-for-obesity-demonstrating-favorable-safety-profile-and-emerging-evidence-of-weight-loss) for Phase 1a study data press release and here (link: https://ir.corbuspharma.com/news-events/events/detail/20251211-corbus-pharma-virtual-webinar-on-crb-913-for-the-treatment-of-obesity) for archived KOL event discussing the findings.

 

•
Anticipated catalyst for CRB-913 in 2026:
o
CANYON-1 Phase 1b dose-ranging 12-week study (n=240) expected to be completed in summer 2026.

 

CRB-601 is an anti-αvβ8 integrin monoclonal antibody (mAB) designed to block the activation of latent TGFβ in the tumor micro-environment to treat solid tumors.

•
Phase 1 dose escalation trial of CRB-601 completed in Q4 2025.
o
Preliminary monotherapy data were presented in November 2025 at the Society for Immunotherapy of Cancer (SITC) 2025.
o
Corbus has deprioritized this program and does not plan to enroll additional patients.

Financial Results for the Quarter and Year Ended December 31, 2025

The Company reported a net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25, for the three months ended December 31, 2025, compared to a net loss of $9.5 million, or a net loss per basic and diluted share of $0.78, for the three months ended December 31, 2024.

Operating expenses increased by $9.4 million to approximately $22.0 million for the three months ended December 31, 2025, compared to approximately $12.6 million for the three months ended December 31, 2024. The increase was primarily attributable to an increase in clinical development expenses.

The Company had $163.3 million of cash, cash equivalents, and investment on hand at December 31, 2025, which is expected to fund operations into 2028 based on planned expenditures. In the fourth quarter of 2025, the Company completed a public offering that raised a total of $75 million in gross proceeds.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage company focused on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set

forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

 

INVESTOR CONTACTS:

Sean Moran

Chief Financial Officer

Corbus Pharmaceuticals

smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

 

MEDIA CONTACT:

Liz Melone

Founder & Principal

Melone Communications, LLC

liz@melonecomm.com

 

---tables to follow---

Corbus Pharmaceuticals Holdings, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

 

 

 

Unaudited
For the Three Months
Ended December 31,

 

 

For the Year Ended
December 31,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

18,406

 

 

$

8,787

 

 

$

70,095

 

 

$

32,222

 

General and administrative

 

 

3,560

 

 

 

3,818

 

 

 

15,215

 

 

 

16,499

 

Total operating expenses

 

 

21,966

 

 

 

12,605

 

 

 

85,310

 

 

 

48,721

 

Operating loss

 

 

(21,966

)

 

 

(12,605

)

 

 

(85,310

)

 

 

(48,721

)

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

 

 

Interest and investment income, net

 

 

1,410

 

 

 

1,782

 

 

 

5,530

 

 

 

6,311

 

Interest expense

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(1,872

)

Other income, net

 

 

1

 

 

 

1,293

 

 

 

1,243

 

 

 

4,073

 

Total other income, net

 

 

1,411

 

 

 

3,075

 

 

 

6,773

 

 

 

8,512

 

Net loss

 

$

(20,555

)

 

$

(9,530

)

 

$

(78,537

)

 

$

(40,209

)

Net loss per share, basic and diluted

 

$

(1.25

)

 

$

(0.78

)

 

$

(5.90

)

 

$

(3.68

)

Weighted average number of common shares outstanding, basic and diluted

 

 

16,482,734

 

 

 

12,179,482

 

 

 

13,317,116

 

 

 

10,915,413

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(20,555

)

 

$

(9,530

)

 

$

(78,537

)

 

$

(40,209

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Change in unrealized (loss) gain on marketable debt securities

 

 

(50

)

 

 

(172

)

 

 

(88

)

 

 

36

 

Total other comprehensive (loss) income

 

 

(50

)

 

 

(172

)

 

 

(88

)

 

 

36

 

Total comprehensive loss

 

$

(20,605

)

 

$

(9,702

)

 

$

(78,625

)

 

$

(40,173

)

 

 

 

 

Corbus Pharmaceuticals Holdings, Inc.

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

 

 

 

December 31, 2025

 

 

December 31, 2024

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

28,492

 

 

$

17,198

 

Investments

 

 

134,777

 

 

 

131,864

 

Restricted cash

 

 

670

 

 

 

285

 

Prepaid expenses and other current assets

 

 

3,015

 

 

 

3,629

 

Total current assets

 

 

166,954

 

 

 

152,976

 

Restricted cash

 

 

—

 

 

 

385

 

Property and equipment, net

 

 

159

 

 

 

385

 

Operating lease right-of-use assets

 

 

1,082

 

 

 

2,133

 

Total assets

 

$

168,195

 

 

$

155,879

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,215

 

 

$

4,786

 

Accrued expenses

 

 

16,844

 

 

 

5,426

 

Operating lease liabilities, current

 

 

1,633

 

 

 

1,606

 

Total current liabilities

 

 

20,692

 

 

 

11,818

 

Operating lease liabilities, noncurrent

 

 

—

 

 

 

1,633

 

Total liabilities

 

 

20,692

 

 

 

13,451

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and December 31, 2024

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value; 300,000,000 shares authorized,
17,611,511 and 12,179,482 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively

 

 

2

 

 

 

1

 

Additional paid-in capital

 

 

702,984

 

 

 

619,285

 

Accumulated deficit

 

 

(555,430

)

 

 

(476,893

)

Accumulated other comprehensive (loss) gain

 

 

(53

)

 

 

35

 

Total stockholders’ equity

 

 

147,503

 

 

 

142,428

 

Total liabilities and stockholders’ equity

 

$

168,195

 

 

$

155,879